v3.26.1
Statements of Stockholders' Equity (FY) - USD ($)
$ in Thousands
Common stock
Additional paidin capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total
Balance at Beginning of period at Dec. 31, 2023   $ 705,794 $ (43) $ (594,468) $ 111,283
Balance at Beginning of period (in shares) at Dec. 31, 2023 2,805,618        
Stockholders' equity          
Issuance of common stock under the ATM Facility, net of offering costs   8,742     8,742
Issuance of common stock under the ATM Facility, net of offering costs (in shares) 300,000        
Exercise of stock options and vesting of restricted stock units   35     35
Exercise of stock options and vesting of restricted stock units (in shares) 45,649        
Issuance of shares in connection with employee stock purchase plan   97     97
Issuance of shares in connection with employee stock purchase plan (in shares) 10,236        
Unrealized gain (loss) on marketable securities     51   51
Sharebased compensation expense   5,820     5,820
Net loss       (64,767) (64,767)
Balance at end of period at Dec. 31, 2024   720,488 8 (659,235) 61,261
Balance at end of period (in shares) at Dec. 31, 2024 3,161,503        
Stockholders' equity          
Exercise of stock options and vesting of restricted stock units (in shares) 4,325        
Unrealized gain (loss) on marketable securities     (8)   (8)
Sharebased compensation expense   858     858
Net loss       (15,405) (15,405)
Balance at end of period at Mar. 31, 2025   721,346   (674,640) 46,706
Balance at end of period (in shares) at Mar. 31, 2025 3,165,828        
Balance at Beginning of period at Dec. 31, 2024   720,488 8 (659,235) 61,261
Balance at Beginning of period (in shares) at Dec. 31, 2024 3,161,503        
Stockholders' equity          
Exercise of stock options and vesting of restricted stock units (in shares) 16,825        
Issuance of shares in connection with employee stock purchase plan   23     23
Issuance of shares in connection with employee stock purchase plan (in shares) 4,482        
Unrealized gain (loss) on marketable securities     $ (8)   (8)
Sharebased compensation expense   3,001     3,001
Net loss       (45,522) (45,522)
Balance at end of period at Dec. 31, 2025   723,512   (704,757) 18,755
Balance at end of period (in shares) at Dec. 31, 2025 3,182,810        
Stockholders' equity          
Exercise of stock options and vesting of restricted stock units (in shares) 25,000        
Sharebased compensation expense   556     556
Net loss       (7,559) (7,559)
Balance at end of period at Mar. 31, 2026   $ 724,068   $ (712,316) $ 11,752
Balance at end of period (in shares) at Mar. 31, 2026 3,207,810